Among these, secukinumab, a fully human IL-17A monoclonal antibody, has been sanctioned for the management of plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, among other conditions. This evidence concerns the gene IL17A and ankylosing spondylitis.